Document Detail

Long-term survival in 618 patients from the Western Washington Streptokinase in Myocardial Infarction trials.
MedLine Citation:
PMID:  1452917     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The aim of this study was to determine whether streptokinase treatment improves long-term survival in patients with acute myocardial infarction. BACKGROUND: Thrombolytic treatment for acute myocardial infarction reduces early mortality and improves the 1-year survival rate, but the long-term (3 to 8 years) survival benefits of treatment and the relation between survival and baseline clinical characteristics, infarct size and ventricular function have not been established. METHODS: We assessed survival status at a minimum of 3 and a mean of 4.9 +/- 2.3 years in 618 patients randomized between 1981 and 1986 to receive conventional treatment (n = 293) or thrombolysis with streptokinase (n = 325) in the Western Washington Intracoronary (n = 250) and Intravenous (n = 368) Streptokinase in Myocardial Infarction trials. The relation between long-term survival and thrombolytic treatment, admission baseline clinical characteristics and late radionuclide tomographic thallium-201 infarct size and ejection fraction was assessed in a subset of patients. RESULTS: Survival at 6 weeks was 94% in patients who received streptokinase versus 88% in the control group (p = 0.01). However, survival at 3 years was 84% in the streptokinase group and 82% in the control group and for the total period of follow-up, there was no significant survival benefit (p = 0.16). Analysis by infarct location showed a higher survival rate at 3 years for patients treated with anterior infarction (76% vs. 67% for the control group), but no overall survival benefit (p = 0.14). Survival at 3 years for patients with an inferior infarction was 89% in the streptokinase group and 91% in the control group (p = 0.62). By stepwise Cox regression analysis, admission clinical variables associated with decreased long-term survival were anterior infarction, advanced age, history of prior infarction and the presence of pulmonary edema or hypotension. Although streptokinase therapy was associated with improved survival, it was not an independent determinant of survival (p = 0.069). Ejection fraction and thallium-201 infarct size measured approximately 8 weeks after enrollment had a strong association with long-term survival. Univariate analysis in a subgroup of 289 patients with complete data selected infarct size, ejection fraction, age and history of prior infarction as predictors of survival. In the multivariate model, only ejection fraction (p < 0.0001), age (p = 0.008) and prior myocardial infarction (p = 0.02) remained strong predictors. CONCLUSIONS: In these early trials of thrombolytic therapy for acute myocardial infarction, streptokinase improved early survival, but there was little long-term survival benefit. This failure to show an improvement in the 3- to 8-year survival rate may also reflect the need to study a larger group of patients or to initiate treatment earlier after symptom onset.
M D Cerqueira; C Maynard; J L Ritchie; K B Davis; J W Kennedy
Related Documents :
8154647 - Holding gusto up to the light. global utilization of streptokinase and tissue plasminog...
8503507 - Clinical and angiographic features of patients with an occluded versus a patent infarct...
8504497 - Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocard...
7721477 - Magnesium deficiency prolongs myocardial stunning in an open-chest swine model.
12234807 - Cardioprotection by multiple preconditioning cycles does not require mitochondrial k(at...
1625367 - In vivo 31p nuclear magnetic resonance spectroscopy in patients with old myocardial inf...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  20     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  1992 Dec 
Date Detail:
Created Date:  1992-12-31     Completed Date:  1992-12-31     Revised Date:  2010-03-24    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1452-9     Citation Subset:  AIM; IM    
Department of Medicine, University of Washington School of Medicine, Seattle.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary / standards
Combined Modality Therapy
Coronary Artery Bypass / standards
Follow-Up Studies
Infusions, Intravenous
Middle Aged
Myocardial Infarction / diagnosis,  drug therapy*,  mortality
Predictive Value of Tests
Proportional Hazards Models
Streptokinase / administration & dosage,  therapeutic use*
Stroke Volume
Survival Rate
Thallium Radioisotopes / diagnostic use
Tomography, Emission-Computed / standards
Treatment Outcome
Washington / epidemiology
Grant Support
Reg. No./Substance:
0/Thallium Radioisotopes; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Invasive versus conservative strategy after thrombolytic therapy for acute myocardial infarction in ...
Next Document:  Additional ST segment elevation during the first hour of thrombolytic therapy: an electrocardiograph...